| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.08 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |